Long-term safety follow-up of people treated with cilta-cel for multiple myeloma
Follows adults with multiple myeloma previously treated with cilta-cel to study late side effects.
Plain-language title generated from the registry record
Registry title: A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Key facts
- Where
- Atlanta, Boston, Buffalo, Charlotte, Chicago, Detroit, Duarte, Hackensack, Houston, Indianapolis, Milwaukee, Nashville, New Brunswick, New York, Philadelphia, Phoenix, Pittsburgh, Rochester, San Francisco, St Louis, Stanford, Tampa, The Bronx, and Westwood, United StatesSee the 28 sites
- Phase
- Phase 4
Where in United States
- Emory UniversityAtlanta, United StatesTaking people
- Beth Israel Deaconess Medical CenterBoston, United StatesTaking people
- Dana-Farber Cancer InstituteBoston, United StatesTaking people
- Massachusetts General HospitalBoston, United StatesTaking people
- Roswell Park Cancer InstituteBuffalo, United StatesTaking people
- Levine Cancer InstituteCharlotte, United StatesTaking people
- Northwestern UniversityChicago, United StatesTaking people
- University of ChicagoChicago, United StatesTaking people
- Barbara Ann Karmanos Cancer InstituteDetroit, United StatesTaking people
- City of HopeDuarte, United StatesTaking people
- Hackensack University Medical CenterHackensack, United StatesTaking people
- MD Anderson Cancer CenterHouston, United StatesTaking people
- Indiana UniversityIndianapolis, United StatesTaking people
- Froedtert MemorialMilwaukee, United StatesTaking people
- Sarah Cannon Research InstituteNashville, United StatesTaking people
- Rutgers Cancer Institute of New JerseyNew Brunswick, United StatesTaking people
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesTaking people
- Mount SInai Medical CenterNew York, United StatesTaking people
- University of PennsylvaniaPhiladelphia, United StatesTaking people
- Mayo Clinic Cancer Center-ScottsdalePhoenix, United StatesTaking people
- University of Pittsburgh Medical CenterPittsburgh, United StatesTaking people
- Mayo Clinic - RochesterRochester, United StatesTaking people
- University of California San FranciscoSan Francisco, United StatesTaking people
- Washington University School of MedicineSt Louis, United StatesTaking people
- Stanford University Medical CenterStanford, United StatesTaking people
- Moffitt Cancer CenterTampa, United StatesTaking people
- Montefiore Medical CenterThe Bronx, United StatesTaking people
- Kansas University Medical CenterWestwood, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Janssen Research & Development, LLC
- Trial code
- NCT05201781EU 2023-505530-10-00
- Record updated
- 3 November 2026
- Original description
The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.Read full original descriptionShow less
Long-term Follow-up Study for Participants Previously Treated With Ciltacabtagene Autoleucel
The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.
Inclusion: Participants who have received at least one dose of cilta-cel in a Company-sponsored clinical study; Participants who have provided informed consent for this study.